Roth Capital’s healthcare analyst Joseph Pantginis reiterated a Buy rating on Galena Biopharma (NASDAQ:GALE) with an $8.00 price target, after the company provided its …
In a research report published today, Roth Capital analyst Joseph Pantginis maintained a Buy rating on Galena Biopharma (NASDAQ:GALE) with an $8.00 price target, as …
In a research report issued today, MLV analyst Vernon Bernardino maintained a Buy rating on Galena Biopharma (NASDAQ:GALE) and raised his price target to $5 …
Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Galena Biopharma (NASDAQ:GALE) with an $8 price target, as the company announced the expected initiation …
In a research report issued today, Maxim Group analyst Jason Kolbert maintained a Buy rating on Galena Biopharma (NASDAQ:GALE) with a price target …
In a research report issued yesterday, Roth Capital analyst Joseph Pantginis reaffirmed a Buy rating on Galena Biopharma (NASDAQ:GALE) with an $8 price target, …
In a research report issued today, Oppenheimer analyst Yigal Nochomovitz reiterated a Perform rating on Galena Biopharma (NASDAQ:GALE), following the company’s third-quarter earnings. …
In a research report published this morning, Maxim Group analyst Jason Kolbert maintained a Buy rating on Galena Biopharma (NASDAQ:GALE) with a price …
In a research note published today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Galena Biopharma (NASDAQ:GALE) with an $8 price target, following the …
